Pipeline Database
UB670
Search clinical-stage assets by therapeutic area, modality, target, indication, stage and territory — then inquire on any row that fits your brief.
UB670
IndicationsDry age-related macular degeneration
ClinicalCN - Preclinical
TherapeuticsOphthalmology
ModalitiesNucleic Acid Therapeutics
Exclusive Summary
- First-in-class CPP (cell-penetrating peptide) siRNA for age-related macular degeneration (AMD), targeting a potential market of $1.6 billion.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →